Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

TerminatedOBSERVATIONAL
Enrollment

117

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Neoplasms, Breast
Trial Locations (29)

1200

GSK Investigational Site, Brussels

5000

GSK Investigational Site, Namur

10126

GSK Investigational Site, Turin

18059

GSK Investigational Site, Rostock

19713

GSK Investigational Site, Newark

20141

GSK Investigational Site, Milan

24105

GSK Investigational Site, Kiel

27100

GSK Investigational Site, Pavia

29414

GSK Investigational Site, Charleston

33081

GSK Investigational Site, Aviano (PN)

33324

GSK Investigational Site, Plantation

44137

GSK Investigational Site, Dortmund

45136

GSK Investigational Site, Essen

60590

GSK Investigational Site, Frankfurt am Main

66421

GSK Investigational Site, Homburg

72076

GSK Investigational Site, Tübingen

79106

GSK Investigational Site, Amarillo

80131

GSK Investigational Site, Napoli

91054

GSK Investigational Site, Erlangen

197022

GSK Investigational Site, Saint Petersburg

197758

GSK Investigational Site, Saint Petersburg

390011

GSK Investigational Site, Ryazan

09116

GSK Investigational Site, Chemnitz

00189

GSK Investigational Site, Rome

BH7 7DW

GSK Investigational Site, Bournemouth

DE22 3DT

GSK Investigational Site, Derby

EH4 2XU

GSK Investigational Site, Edinburgh

NG5 1PB

GSK Investigational Site, Nottingham

BH15 2JB

GSK Investigational Site, Poole

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01476111 - Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer | Biotech Hunter | Biotech Hunter